Taysha Gene Therapies, Inc. reports company developments as a clinical-stage biotechnology company advancing adeno-associated virus, or AAV, gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is an intrathecally delivered, self-complementary AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
Recurring updates cover TSHA-102 clinical and preclinical data, FDA regulatory interactions and designations, manufacturing and comparability topics, financial results, corporate updates, and employee inducement equity grants under Nasdaq listing rules. Company communications also describe the program’s MECP2 construct design, miRARE technology, and clinical trial activity in Rett syndrome.
Taysha Gene Therapies (TSHA) granted equity awards to four new employees on October 1, 2026, as inducements to enter employment.
The awards comprise restricted stock units (RSUs) representing 384,000 common shares and an option to purchase 92,400 common shares under the 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). RSUs are awards that vest into shares. They vest in four equal annual installments beginning on the first anniversary of the vesting commencement date. The option's $4.74 exercise price equals the closing share price on the grant date. It vests over four years: 25% on the first anniversary of the vesting commencement date and the remaining 75% monthly over the next 36 months. Both awards require continued service at each vesting date.
Taysha Gene Therapies (TSHA) announced encore presentations on its investigational TSHA-102 Rett syndrome program at the Child Neurology Society Annual Meeting. The 55th annual meeting takes place in Montréal, Québec, Canada, on October 14–17, 2026. The presentations cover data previously shared at the 2026 International Rett Syndrome Foundation Scientific Meeting.
An October 15 oral presentation and poster will address safety and efficacy in pediatric and adolescent/adult cohorts of the REVEAL Part A Phase 1/2 trial. Other posters address Rett syndrome natural history and a developmental milestone assessment as a primary endpoint for interventional studies. Taysha will also host an October 16 symposium on Rett syndrome across the disease continuum, featuring Elsa Rossignol, Jeffrey Neul and Tessa Clarkson.
Taysha Gene Therapies (TSHA) granted equity awards to five new employees on September 1, 2026 under its 2023 Inducement Plan. The awards comprise restricted stock units (RSUs) for 314,000 shares of common stock and stock options for 92,400 shares, granted as employment inducements under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments starting on the first anniversary of the vesting commencement date, subject to continued service. The stock options have a $5.70 exercise price, a 10-year term, and vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on ongoing employment.
Taysha Gene Therapies (Nasdaq: TSHA) reported second quarter 2026 results and advanced its Rett syndrome program TSHA-102. Revenue was $0 versus $1.986 million a year ago, with research and development expenses rising to $38.6 million and general and administrative expenses to $12.1 million. Net loss widened to $46.6 million, or $0.13 per share.
The company completed dosing in the overenrolled REVEAL pivotal trial (N=17) and ASPIRE trial (N=4), with TSHA-102 generally well tolerated across 33 treated patients and no severe treatment-related SAEs or DLTs. Longer-term REVEAL Part A data showed multi-domain functional gains through at least 12 months.
Taysha completed a $230 million follow-on offering, ending June 30, 2026 with $455.4 million in cash and cash equivalents and expecting runway into 2H 2028. Commercial readiness progressed via payer research and an expanded Catalent manufacturing partnership. BLA-enabling PPQ for TSHA-102 is expected in Q4 2026, with pivotal 6‑month interim data and FDA feedback anticipated in 1H 2027.
Taysha Gene Therapies (Nasdaq: TSHA) will report second quarter 2026 financial results and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. The live and archived webcast will be accessible via the Events and Presentations page of Taysha’s investor relations website.
Taysha Gene Therapies (Nasdaq: TSHA) and Catalent have expanded their strategic partnership with a commercial supply agreement for TSHA-102, Taysha’s investigational AAV-based gene therapy in pivotal development for Rett syndrome. Under the agreement, Catalent will serve as Taysha’s primary commercial manufacturer following potential U.S. FDA approval.
The deal secures long-term GMP manufacturing capacity and a scalable supply framework at Catalent’s FDA-licensed gene therapy facility in Harmans, Maryland, which supports more than 90 gene therapy programs, including multiple commercial products. Taysha reports that BLA-enabling Process Performance Qualification activities for TSHA-102 are underway, aligning manufacturing readiness with a potential future commercial launch.
Taysha Gene Therapies (Nasdaq: TSHA) will present multiple updates on its TSHA-102 Rett syndrome program at the 2026 IRSF Rett Syndrome Scientific Meeting in Prior Lake, MN, from June 29–July 1, 2026.
Topics include longer-term REVEAL Part A clinical data, Rett natural history, validation of the Rett Syndrome Developmental Milestone Assessment as a primary endpoint, and preclinical MeCP2 expression data supporting TSHA-102 intrathecal AAV9 delivery.
Taysha Gene Therapies (Nasdaq: TSHA) priced an underwritten public offering of 32,500,001 common shares at $6.00 per share and pre-funded warrants for 833,333 shares at $5.999 each. Expected gross proceeds are about $200 million, excluding any underwriter option exercise.
The company granted underwriters a 30-day option for up to 5,000,000 additional shares. Closing is expected on or about June 26, 2026, subject to customary conditions.
Taysha Gene Therapies (Nasdaq: TSHA) began an underwritten public offering of approximately $200.0 million of common stock and pre-funded warrants. All securities are offered by the company, with underwriters granted a 30-day option to buy up to an additional 15% of the shares. The deal is subject to market conditions and will be issued under an effective shelf registration filed in November 2025.
Taysha Gene Therapies (Nasdaq: TSHA) completed dosing of 17 patients in the REVEAL pivotal trial of TSHA-102 for Rett syndrome and reported longer-term Part A Phase 1/2 data.
All 12 Part A patients gained/regained ≥one developmental milestone, with ~26 functional gains per patient and no treatment-related SAEs or DLTs. Topline pivotal interim data and FDA feedback are expected 1H 2027.